Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Janux Therapeutics (JANX) Shares Outstanding (2020 - 2025)

Janux Therapeutics (JANX) has disclosed Shares Outstanding for 6 consecutive years, with $60.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Outstanding rose 2.23% to $60.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $60.4 million, a 2.23% increase, with the full-year FY2025 number at $60.4 million, up 2.23% from a year prior.
  • Shares Outstanding was $60.4 million for Q4 2025 at Janux Therapeutics, roughly flat from $60.1 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $60.4 million in Q4 2025 to a low of $1.2 million in Q1 2021.
  • A 5-year average of $46.1 million and a median of $44.0 million in 2023 define the central range for Shares Outstanding.
  • Peak YoY movement for Shares Outstanding: surged 4383.61% in 2021, then increased 0.88% in 2023.
  • Janux Therapeutics' Shares Outstanding stood at $41.2 million in 2021, then rose by 0.9% to $41.6 million in 2022, then increased by 11.14% to $46.3 million in 2023, then increased by 27.7% to $59.1 million in 2024, then grew by 2.23% to $60.4 million in 2025.
  • Per Business Quant, the three most recent readings for JANX's Shares Outstanding are $60.4 million (Q4 2025), $60.1 million (Q3 2025), and $59.3 million (Q2 2025).